ACADIA Pharmaceuticals Inc (ACAD) stock news · P/E 8.8, rev $1.07B
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
This ACAD news page leads with what ACADIA Pharmaceuticals Inc filed — not a scraped headline mill.
No cached 8-K sentence for ACAD yet. We will not pad this page with generic market recap.
Latest reported ACAD revenue for 2025-12-31 was $1.07B. Net income was $391.0M. Revenue was up 11.9% from 2024-12-31 to 2025-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 8.8.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the ACAD stock page; for the tape open the quote page.
ACAD stock news FAQ
What are ACAD's latest revenue and net income?
Latest cached ACADIA Pharmaceuticals Inc (ACAD) revenue for Dec 31, 2025 was $1.07B. Net income was $391.0M. Statements: https://lician.com/financials/acad
How did ACAD revenue change from the prior cached period?
Cached ACADIA Pharmaceuticals Inc (ACAD) revenue was up 11.9% from $957.8M (Dec 31, 2024) to $1.07B (Dec 31, 2025). Statements: https://lician.com/financials/acad
What is ACAD's P/E ratio?
ACADIA Pharmaceuticals Inc (ACAD) trailing P/E is 8.85 on the latest cached fundamentals snapshot.
What is ACAD's market cap?
ACADIA Pharmaceuticals Inc (ACAD) market cap is $3.51B on the latest cached fundamentals snapshot.
What kind of company is ACAD?
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Where is ACAD stock news listed?
Cached stock news for ACADIA Pharmaceuticals Inc (ACAD) is listed at https://lician.com/news/acad. Filings: https://lician.com/sec/acad
Not investment advice.